Acceptance rate 46%
Time to first decision 20 days*
Time to decision with review 50 days*

*Approximate number of days

**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.

ACTA Pharmaceutica Sciencia 2021 , Vol 59 , Num 2
Synthesis of New 1,2,4-Triazole Derivatives and Investigation of Their Matrix Metalloproteinase-9 (MMP-9) Inhibition Properties
Leyla Yurttaş 1 Asaf Evrim Evren 1-2 Aslıhan Kubilay 3 Halide Edip Temel 4
1 Anadolu University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, 26470, Eskişehir, Turkey
2 Vocational School of Health Services, Bilecik Şeyh Edebali University, Bilecik, Turkey
3 Anadolu University, Faculty of Pharmacy, Department of Analytical Chemistry, 26470, Eskişehir, Turkey
4 Anadolu University, Faculty of Pharmacy, Department of Biochemistry, 26470, Eskişehir, Turkey
DOI : 10.23893/1307-2080.APS.05913 Nine new 2-[[5-((4-acetamidophenoxy)methyl)-4-phenyl-4H-1,2,4-triazol-3-yl] thio]-N-(aryl/heteroaryl)acetamide (5a-5i) derivatives were synthesized and tested for their matrix metalloproteinase-9 (MMP-9) inhibition potency which is associated with antiproliferative activity. None of the compounds exhibited MMP-9 inhibition activity close to standard drug however, two compounds 5e bearing 6-methylbenzothiazole and 5g bearing 6-ethoxybenzothiazole moieties showed the highest MMP-9 inhibition which were determined over than 50% percentage at 100 µg/mL concentration. Some physicochemical properties of all final compounds were calculated via SwissADME and the results were modest to be able to an oral drug. Molecular docking studies were realized with MMP-9 enzyme (PDB ID: 5I12) and 5d, 5e, and 5g compounds for comparing the active and non-active/low effective structures. Keywords : 1,2,4-Triazole, matrix metalloproteinase-9 (MMP-9), antiproliferative activity, molecular docking

Istanbul Medipol University